Clinuvel PharmaceuticalsASX:CUV -0.60%81 Median PS Value is A$62.30 as of Jun. 27, 2026, which is 100% below its 10-year median of 0.27. GuruFocus rates ASX:CUV with a GF Score™ of 81/100 and a GF Value™ of A$17.71 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 276 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 89.86% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Clinuvel Pharmaceuticals's Median PS Value or its related term are showing as below:
ASX:CUV'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16 Med: 0.27 Max: 0.73
Current: 0.16
During the past 13 years, the highest Price to Median PS Value of Clinuvel Pharmaceuticals was 0.73. The lowest was 0.16. And the median was 0.27.
ASX:CUV's Price-to-Median-PS-Value is ranked better than 89.86% of 276
companies
in the Biotechnology industry
Industry Median: 0.62
vs ASX:CUV: 0.16
Clinuvel Pharmaceuticals (ASX:CUV) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Clinuvel Pharmaceuticals's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
9.99
/
62.30
=
0.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals Median PS Value Related Terms
Clinuvel Pharmaceuticals Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CUV vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 32.6863.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.906.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals (ASX:CUV) has a Median PS Value of A$62.30 as of Jun. 27, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Clinuvel Pharmaceuticals and its competitors. This is 22974% above median its historical median of 0.27. Over the past decade, Clinuvel Pharmaceuticals' Median PS Value has ranged from 0.16 to 0.73. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #28 out of 276 companies in the Biotechnology industry, placing it in the top 10.1%.
Is Clinuvel Pharmaceuticals' Median PS Value too high?
Clinuvel Pharmaceuticals' current Median PS Value of A$62.30 is 22974% above median its 10-year median of 0.27. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 0.73. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #28 out of 276 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #28 out of 276 companies for Median PS Value. This places Clinuvel Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.62. Historically, Clinuvel Pharmaceuticals' own Median PS Value has ranged from 0.16 to 0.73 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Clinuvel Pharmaceuticals and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current Median PS Value is A$62.30, which is 22974% above median its own 10-year median of 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.71, compared to a current price of A$9.99 — trading 43.6% below its estimated fair value. The current Median PS Value is A$62.30, which is 22974% above median its 10-year median of 0.27. Clinuvel Pharmaceuticals' overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current Median PS Value is A$62.30 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of A$9.99 is trading 43.6% below its estimated GF Value™ of A$17.71.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ASX:CUV:
Median PS Value: A$62.30 (22974% above median its 10-year median of 0.27)
GF Value™: A$17.71 vs. price of A$9.99 (43.6% below fair value)
No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
81GF Score
Get the complete analysis for ASX:CUV
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CUV has been successfully added to your 
